John Climax Biography and Net Worth

Director of Icon

Dr. John Climax, one of ICON’s co-founders, served as Chair of the Board of ICON plc from November 2002 to December 2009 and as Chief Executive Officer from June 1990 to October 2002. Since January 2010 he has held a position as a Non-Executive Director and Emeritus Chair of the ICON plc. In 2004 he established the Human Dignity Foundation, a Swiss charity dedicated to protecting vulnerable children from sexual exploitation and abuse. Dr. Climax has over 30 years of experience in the clinical research industry.

Dr. Climax received his primary degree in Pharmacy from the University of Singapore, his Masters in Applied Pharmacology from the University of Wales and his Doctorate in Clinical Pharmacology from the National University of Ireland. He has authored a significant number of papers and presentations and is a holder of numerous active patents. Dr. Climax is an adjunct Professor at the Royal College of Surgeons in Ireland. He is currently Executive Chairman of DS Biopharma and Chairman and CEO of Afimmune, both of which are private companies.

What is John Climax's net worth?: The estimated net worth of John Climax is at least $337.78 thousand as of September 16th, 2026. Dr. Climax owns 2,087 shares of Icon stock worth more than $337,781 as of October 2nd. This net worth evaluation does not reflect any other investments that Dr. Climax may own. Learn More about John Climax's net worth.
How do I contact John Climax?: The corporate mailing address for Dr. Climax and other Icon executives is South County Business Park, Dublin, DU, D18 X5R3. Icon can also be reached via phone at (531) 291-2000. Learn More on John Climax's contact information.
Has John Climax been buying or selling shares of Icon?: John Climax has not been actively trading shares of Icon during the last quarter. Most recently, John Climax sold 5,005 shares of the business's stock in a transaction on Wednesday, September 16th. The shares were sold at an average price of $175.00, for a transaction totalling $875,875.00. Following the completion of the sale, the director now directly owns 2,087 shares of the company's stock, valued at $365,225. Learn More on John Climax's trading history.
Who are Icon's active insiders?: Icon's insider roster includes Barry Balfe (CEO), Brennan Brendan (CFO), Bernard Clerkin (CFO), John Climax (Director), Linda Grais (Director), Eugene Mccague (Director), Ronan Murphy (Director), Ciaran Murray (Director), and Anne Whitaker (Director). Learn More on Icon's active insiders.
Are insiders buying or selling shares of Icon?: In the last year, insiders at the medical research company sold shares 11 times. They sold a total of 22,796 shares worth more than $3,887,138.95. The most recent insider tranaction occured on September, 17th when Director Eugene Pacelli Mccague sold 3,255 shares worth more than $569,625.00. Insiders at Icon own 44.0% of the company. Learn More about insider trades at Icon.
Information on this page was last updated on 9/17/2026.

John Climax Insider Trading History at Icon

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/16/2026	Sell	5,005	$175.00	$875,875.00	2,087
8/11/2026	Sell	841	$164.29	$138,167.89	2,087

John Climax Buying and Selling Activity at Icon

Icon Company Overview

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, it offers adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

Today's Range

Now: $161.85

$160.90

$170.22

50 Day Range

MA: $167.35

$156.70

$180.24

2 Week Range

Now: $161.85

$66.57

$203.91

Volume

677,175 shs

Average Volume

1,033,399 shs

Market Capitalization

$12.39 billion

P/E Ratio

37.99

Dividend Yield

N/A

Beta

1.24